BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 8761364)

  • 1. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).
    Antoniw P; Farnsworth AP; Turner A; Haines AM; Mountain A; Mackintosh J; Shochat D; Humm J; Welt S; Old LJ; Yarranton GT; King DJ
    Br J Cancer; 1996 Aug; 74(4):513-24. PubMed ID: 8761364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
    Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
    Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.
    King DJ; Antoniw P; Owens RJ; Adair JR; Haines AM; Farnsworth AP; Finney H; Lawson AD; Lyons A; Baker TS
    Br J Cancer; 1995 Dec; 72(6):1364-72. PubMed ID: 8519646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle.
    Casey JL; King DJ; Pedley RB; Boden JA; Boden R; Chaplin LC; Dorning M; Begent RH
    Br J Cancer; 1998 Nov; 78(10):1307-12. PubMed ID: 9823971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
    Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
    Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
    Domingo RJ; Reilly RM
    Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
    Buchsbaum DJ; Lawrence TS; Roberson PL; Heidorn DB; Ten Haken RK; Steplewski Z
    Int J Radiat Oncol Biol Phys; 1993 Mar; 25(4):629-38. PubMed ID: 8454481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
    Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
    Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
    Behr TM; Memtsoudis S; Sharkey RM; Blumenthal RD; Dunn RM; Gratz S; Wieland E; Nebendahl K; Schmidberger H; Goldenberg DM; Becker W
    Int J Cancer; 1998 Aug; 77(5):787-95. PubMed ID: 9688314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
    Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z
    Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting.
    Chinol M; Paganelli G; Sudati F; Meares C; Fazio F
    Nucl Med Commun; 1997 Feb; 18(2):176-82. PubMed ID: 9076775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
    King DJ; Turner A; Farnsworth AP; Adair JR; Owens RJ; Pedley RB; Baldock D; Proudfoot KA; Lawson AD; Beeley NR
    Cancer Res; 1994 Dec; 54(23):6176-85. PubMed ID: 7954464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.
    Borchardt PE; Vriesendorp HM; Freedman RS; Quadri SM
    Cancer Biother Radiopharm; 2004 Feb; 19(1):43-51. PubMed ID: 15068610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
    O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.